Research
Metabolic adaptation
Heterogeneous results were observed regarding the degree of glycemic control associated with optimal macrovascular disease risk reduction.
Clinicians should be aware of the variability in glycemic control outcomes when treating T2DM.
StrongQualifiesmedium confidence
Heterogeneous results pertaining to the degree of glycemic control associated with optimal macrovascular disease risk reduction, as well as the safest pharmacologic means to do so, were observed.
Why this rating
The review of multiple trials provides a strong basis for this claim.
Source
Cardiovascular Outcomes Trials in Type 2 Diabetes Mellitus
Karan Kapoor et al. · Cardiology · 2016
DOI 10.1159/000446471
reviewCited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- The post-ACCORD era represents a significant shift in the landscape of cardiovascular outcomes trials (CVOTs) in type 2 diabetes mellitus (T2DM), emphasizing the safety of glucose-lowering agents.Strong
- Recently completed and ongoing trials of dipeptidyl peptidase-4 inhibitors and sodium-glucose cotransporter 2 inhibitors will inform clinical practice on safe and effective ways to reduce cardiovascular risk in T2DM.Strong
Related findings · Metabolic adaptation
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →